



Statement by Rick Barry at the Filana 2026 Annual Meeting of Stockholders – June 11, 2026

Good morning,

It has been difficult for us to discuss much of substance with our investors since Filana's IND was placed on Full Clinical Hold by the FDA late last year.

We have been working very diligently to generate answers to the concerns raised by the FDA. Our team has performed a large number of pre-clinical experiments with the aim of generating the appropriate data that would answer FDA's questions. We have been scientifically thorough and diligent as we have endeavored to generate the information that FDA needs. We are aiming to provide you with an update on the status of our clinical hold in the coming months.

There are several things you should know:

1. We have built an organization that is ready to move forward with our TSC-related epilepsy program. As you should already know, Dr. Angelique Bordey, one of the world's recognized experts in TSC, joined us last year as our SVP of Neuroscience. Dr. Joe Hulihan joined us as well last year as Chief Medical Officer. Joe is a neurologist and epileptologist who has run a large Phase 3 program in TSC-related epilepsy with Marinus. Our clinical group, led by Dr. Jack Moore, is ready to get started.
2. We have worked very closely with the TSC Alliance who has been a wonderful partner. Through the Alliance, we have met with the leading clinicians and clinical trial sites for this indication. Interest in participating in our proof-of-concept study remains high. Once we are successful in providing FDA with enough information for them to remove the Clinical Hold, we will have a lot to share about our trial.
3. We have continued to engage with experts in the scientific community. We have received valuable input about how to interpret the results we hope to achieve in our proof-of-concept study.
4. We know, as Tom Petty says, that "The Waiting is the Hardest Part." I just want you to understand that we are being very careful and deliberate in generating the data that FDA requested. It's been time consuming and the delay has been frustrating. But we know that TSC patients and their families need new treatments options to deal with this disease. Our two published and successful animal models in this indication give us confidence to move forward with our clinical trial. We are here to make a difference.

**Forward-Looking Statements**

This communication contains forward-looking statements based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially due to various factors, including market conditions, industry developments, and the Company's execution of its strategy. The Company undertakes no obligation to update these statements except as required by law.